home / stock / itrm / itrm news

ITRM News and Press, Iterum Therapeutics plc

Stock Information
Company Name: Iterum Therapeutics plc
Stock Symbol: ITRM
Market: NASDAQ
Website: iterumtx.com
Menu
ITRM ITRM Quote ITRM Short ITRM News ITRM Articles ITRM Message Board
Get ITRM Alerts

News, Short Squeeze, Breakout and More Instantly...
ITRM - US Companies Moving the Markets, Morning edition
Tue, Jul 16, 2024 as of 10.00 am ET

A look at the top 10 most actives in the United States Conduit Pharmaceuticals Inc. (CDT) rose 40.0% to $0.3361 on volume of 63,970,490 shares Yoshitsu Co. Ltd (TKLF) rose 64.0% to $0.5024 on volume of 62,618,792 shares Silo Pharma Inc. (SILO) rose 91.8% to $2.0522 on volume of 59,055,593...
ITRM - Iterum to face AdCom as FDA reviews lead asset

2024-06-21 12:37:40 ET More on Iterum Therapeutics Iterum Therapeutics plc (ITRM) Q1 2024 Earnings Call Transcript Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript Iterum Therapeutics Non-GAAP EPS of -$0.38 beats by $0.16 Iterum Therapeutics re...

ITRM - Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

DUBLIN, Ireland and CHICAGO, June 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community...

ITRM - Iterum Therapeutics to Present Data at ASM Microbe 2024

DUBLIN and CHICAGO, June 05, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hosp...
ITRM - Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

DUBLIN and CHICAGO, May 31, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospi...

ITRM - Iterum Therapeutics plc (ITRM) Q1 2024 Earnings Call Transcript

2024-05-13 09:49:09 ET Iterum Therapeutics plc (ITRM) Q1 2024 Earnings Conference Call May 13, 2024 08:30 A.M. ET Company Participants Louise Barrett - SVP, Legal Affairs Corey N. Fishman - CEO Judith M. Matthews - CFO Conference Call Participants Mic...

ITRM - Iterum Therapeutics Non-GAAP EPS of -$0.38 beats by $0.16

2024-05-13 07:02:24 ET More on Iterum Therapeutics Iterum Therapeutics resubmits new drug application to U.S. FDA for oral sulopenem Iterum Therapeutics Non-GAAP EPS of -$0.81 Seeking Alpha’s Quant Rating on Iterum Therapeutics Historical earnings data...
ITRM - Expected US Company Earnings on Monday, May 13th, 2024

Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...

ITRM - Iterum Therapeutics Reports First Quarter 2024 Financial Results

- -NDA Resubmitted; FDA Action Expected in Early Q4 24-- - -Cash Runway into 2025, including through Potential FDA Approval-- --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN, Ireland and CHICAGO, May 13, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutic...

ITRM - Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024

DUBLIN, Ireland and CHICAGO, May 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community ...
Next 10